血液透析患者におけるリン吸着剤としての炭酸カルシウム

山田 幸代, 富沢 恵子, 三好 かよ子, 堀江 好美, 島田 明美, 加納 秀美, 田村 和美, 吉野 弘規, 荒井 ゆき子, 宮崎 良一, 藤田 幸雄

doi:10.4009/jsdt1985.22.185

書誌事項

タイトル別名

Calcium carbonate as a phosphate binder in hemodialysis patients
Assessment of its efficacy and limitation from the nursing standpoint
その効果と問題点の看護面からの検討

説明

We evaluated, from the nursing standpoint, the effectiveness and limitations of calcium carbonate as a phosphate binder in 25 patients receiving hemodialysis.<br>Oral aluminum hydroxide gel was discontinued, and the same dose of calcium carbonate was substitued at the start. The dosage of calcium carbonate and 1α (OH) D₃ were adjusted accordingly, aming to keep serum Ca below 11.0mg/dl and serum phosphorus below 7.0mg/dl. Five patients dropped out of the study, 2 because of gastrointestinal distress, and 3 because of hyperphosphatemia. After 12 months on this regimen, the serum aluminum concentration in 20 patients whose hyperphosphatemia was controlled with calcium carbonate alone had fallen significantly from 92.4±43.1 to 34.3±10.5μg/l (p<0.01). Tansient hypercalcemia. (>10.8mg/dl) was observed in ten of the 20 patients. At the final obsevation, mean serum Ca, phosphorus and AI-p were unchanged, while serum PTH increased significantly (p<0.05).<br>About half of the patients complained that it was more difficult to take cailcium carbonate than aluminum hydroxide gel, because the former was in powder form.<br>After dietary phosphate reistriction, the serum phosphate level in 3 patients showing hyperphosphatemia decreased and aluminum hydroxide gel was stopped.<br>We considered education about low phophate diet necessary in patients with hyperphosphatemia undergoing calcium carbonate therapy.

収録刊行物

日本透析療法学会雑誌

日本透析療法学会雑誌 22 (2), 185-190, 1989

社団法人日本透析医学会

キーワード

詳細情報詳細情報について

CRID: 1390282679651448704

NII論文ID: 130003720848

DOI: 10.4009/jsdt1985.22.185

ISSN: 18846211; 09115889

本文言語コード: ja

データソース種別

JaLC
Crossref
CiNii Articles

抄録ライセンスフラグ: 使用不可

書き出し

問題の指摘